Eisai and Biogen Idec Partner to Advance Alzheimer’s Disease Drug Candidates
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 3 (Table of Contents)
Published: 18 Mar-2014
DOI: 10.3833/pdr.v2014.i3.2015 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Biogen Idec and Eisai have joined forces to co-develop and co-commercialise drug candidates that address multiple mechanisms in Alzheimer’s disease (AD), beginning with two clinical-stage drugs from Eisai’s pipeline: the BACE (β-site amyloid precursor protein cleaving enzyme) inhibitor E2609; and BAN2401, an anti-amyloid beta (Aβ) monoclonal antibody...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS